184 related articles for article (PubMed ID: 23509157)
41. Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-beta1 is mediated by caspase-dependent and -independent processes.
Wierenga AT; Schuringa JJ; Eggen BJ; Kruijer W; Vellenga E
Leukemia; 2002 Apr; 16(4):675-82. PubMed ID: 11960349
[TBL] [Abstract][Full Text] [Related]
42. A role for Syk-kinase in the control of the binding cycle of the beta2 integrins (CD11/CD18) in human polymorphonuclear neutrophils.
Willeke T; Schymeinsky J; Prange P; Zahler S; Walzog B
J Leukoc Biol; 2003 Aug; 74(2):260-9. PubMed ID: 12885943
[TBL] [Abstract][Full Text] [Related]
43. Syk is required for integrin signaling in neutrophils.
Mócsai A; Zhou M; Meng F; Tybulewicz VL; Lowell CA
Immunity; 2002 Apr; 16(4):547-58. PubMed ID: 11970878
[TBL] [Abstract][Full Text] [Related]
44. Cross-linking of integrins induces tyrosine phosphorylation of the proto-oncogene product Vav and the protein tyrosine kinase Syk in human factor-dependent myeloid cells.
Gotoh A; Takahira H; Geahlen RL; Broxmeyer HE
Cell Growth Differ; 1997 Jun; 8(6):721-9. PubMed ID: 9186005
[TBL] [Abstract][Full Text] [Related]
45. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
48. Spleen tyrosine kinase mediates the actions of EPO and GM-CSF and coordinates with TGF-β in erythropoiesis.
Chang HC; Huang DY; Wu MS; Chu CL; Tzeng SJ; Lin WW
Biochim Biophys Acta Mol Cell Res; 2017 Apr; 1864(4):687-696. PubMed ID: 28131718
[TBL] [Abstract][Full Text] [Related]
49. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
50. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
51. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
52. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
53. Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition.
Brattås MK; Hemsing AL; Rye KP; Hatfield KJ; Reikvam H
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499034
[TBL] [Abstract][Full Text] [Related]
54. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
55. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1.
Miranti CK; Leng L; Maschberger P; Brugge JS; Shattil SJ
Curr Biol; 1998 Dec; 8(24):1289-99. PubMed ID: 9843681
[TBL] [Abstract][Full Text] [Related]
56. Lipid Raft is required for PSGL-1 ligation induced HL-60 cell adhesion on ICAM-1.
Xu T; Liu W; Luo J; Li C; Ba X; Ampah KK; Wang X; Jiang Y; Zeng X
PLoS One; 2013; 8(12):e81807. PubMed ID: 24312591
[TBL] [Abstract][Full Text] [Related]
57. Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia.
Ghoshal Gupta S; Baumann H; Wetzler M
Leuk Res; 2008 Jul; 32(7):1005-14. PubMed ID: 18192010
[TBL] [Abstract][Full Text] [Related]
58. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
59. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
60. The monocyte Fcgamma receptors FcgammaRI/gamma and FcgammaRIIA differ in their interaction with Syk and with Src-related tyrosine kinases.
Huang ZY; Hunter S; Kim MK; Chien P; Worth RG; Indik ZK; Schreiber AD
J Leukoc Biol; 2004 Aug; 76(2):491-9. PubMed ID: 15136586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
